Compare SIRI & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIRI | QGEN |
|---|---|---|
| Founded | 2013 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.2B |
| IPO Year | 1996 | 1998 |
| Metric | SIRI | QGEN |
|---|---|---|
| Price | $29.90 | $41.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $28.86 | ★ $45.76 |
| AVG Volume (30 Days) | ★ 3.6M | 2.9M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | 4.03% | ★ 7.17% |
| EPS Growth | ★ 136.32 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $5,425,129,000.00 | N/A |
| Revenue This Year | $1.81 | $8.18 |
| Revenue Next Year | $0.67 | $5.71 |
| P/E Ratio | $41.49 | ★ $24.01 |
| Revenue Growth | ★ 8.13 | N/A |
| 52 Week Low | $19.77 | $32.53 |
| 52 Week High | $31.42 | $57.82 |
| Indicator | SIRI | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 61.04 |
| Support Level | $25.30 | $38.24 |
| Resistance Level | $30.11 | $42.33 |
| Average True Range (ATR) | 0.72 | 1.28 |
| MACD | -0.17 | -0.07 |
| Stochastic Oscillator | 32.74 | 58.12 |
Sirius XM operates almost exclusively in the US through its SiriusXM and Pandora audio services. SiriusXM is primarily a satellite radio service that offers nationwide coverage and mostly ad-free listening, with proprietary channels and exclusive content. It makes agreements with automakers to install its radios in vehicles and give trial services to vehicle buyers, which have traditionally fed its subscriber base. The company provides the service via a fleet of geostationary satellites it owns and operates and now offers a streaming SiriusXM option. Pandora, which accounts for a much smaller portion of revenue and profit, offers a subscription and ad-supported streaming music service that competes with industry giants such as Spotify, Apple Music, and YouTube Music.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).